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Vaccines for Lung Cancer
Edward A. Hirschowitz, MD,*† David M. Hiestand, MD,* and John R. Yannelli, PhD‡
Abstract: Immunotherapy is based on the knowledge that the
immune system can distinguish cancerous cells from normal cells.
Conceptually, this is an attractive adjuvant approach because it is
highly specific and can deal with disseminated disease with minimal
impact on normal tissues. In this review, we focus on strategies that
use host immune machinery to generate anti-tumor effects, known as
active immunotherapy. Proof of principle in lung cancer is now well
established in clinical trials, although no superior approach has been
defined and therapeutic efficacy remains unknown. In this review, we
discuss rationale, biological theory, application, and clinical implemen-
tation to date.
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A number of nonconventional therapeutic modalities arebeing developed to improve unacceptably poor outcomes
in lung cancer. In this review, we focus on immunotherapy in
lung cancer with an emphasis on those strategies that use host
immune machinery to generate anti-tumor effects, known as
active immunotherapy. We discuss rationale, biological the-
ory, application, and clinical implementation to date.
Targeting Lung Cancer
Immunotherapy is an attractive targeted therapy for
lung cancer, especially when used in an adjuvant setting after
definitive surgical or nonsurgical therapy with conventional
approaches. The low risk and high potential benefit of tumor
vaccines is especially appealing. Although efficacy has not
yet been proven in lung cancer, the side-effect profile seems
to be quite benign. This risk to benefit ratio is especially
relevant among patients with surgically resected non–small-
cell lung cancer (NSCLC), for whom we cannot yet predict
recurrence beyond statistical probability. Because 70% of
recurrences are systemic, a therapy that can treat dissemi-
nated disease is also highly relevant. Microscopic residual
disease that leads to recurrence among these patients is
perhaps the most amenable target for immunotherapy. Pa-
tients with advanced-stage disease, especially those individ-
uals with large tumor burden, have not been widely viewed as
likely to benefit from immunotherapy, although enhanced
anti-tumor immunity may help to slow disease progression in
this population. The terminal prognosis of advanced-stage
NSCLC and the ability to accurately define tumor progression
and survival make this population a logical choice for clinical
trials. Immunotherapy for small-cell lung cancer (SCLC) has not
been as widely investigated. The disease tends to be very
aggressive, and immunotherapy has not been widely regarded as
having a significant potential to affect outcomes. Because SCLC
is an exclusively nonsurgical disease, the tumor is not routinely
available for autologous vaccine production. The lack of patho-
logic specimens has also slowed preclinical investigation (in the
same way readily available NSCLC specimens have facilitated
study) because SCLC is not available for in vitro study or
xenogeneic tumor modeling, and there is no appropriate SCLC
animal model. Regardless, the poor prognosis associated with
SCLC makes it a rational choice for further investigation.
Targeted Therapies
Based on poor treatment outcomes in advanced-stage
lung cancer, investigation of therapies that may consolidate
clinical responses to chemotherapy and radiation is war-
ranted. Similarly, adjuvant therapies that destroy small resid-
ual disease after surgical resection are highly attractive.
Novel therapies should improve outcomes but have a side
effect profile that is more favorable than conventional che-
motherapy. A number of nonconventional therapeutic ap-
proaches that selectively target malignant cells or their mi-
croenvironment but leave normal cells intact are being
developed. An ideal agent should also be easy to administer
to address both quality of life issues and compliance con-
cerns. Targeted therapies can be divided into three main
groups: (1) pharmacological agents, including small molecule
inhibitors and antisense oligonucleotides; (2) gene therapy;
and (3) immunotherapy (passive and active). Importantly, this
categorization is somewhat artificial because there is signif-
icant overlap among each of these approaches. In light of the
favorable risk to benefit ratio of these approaches and the
potential for combining several targeted therapies with dif-
ferent mechanisms of action to enhanced therapeutic effect, a
brief discussion of each strategy is warranted.
Pharmacological Agents and Small-Molecule
Inhibitors
Most pharmacological agents used to date are DNA-
active drugs, which have limited efficacy and considerable
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toxicity. In recent years, advances in the understanding of
molecular genetics and tumor biology have elucidated the
molecular pathways implicated in the pathogenesis and pro-
gression of cancers. In turn, pharmacological agents that
target molecular pathways responsible for mitogenesis, sur-
vival, migration, invasion, and angiogenesis (the malignant
phenotype) have been developed; some may also prevent
malignant transformation. Pharmacological tyrosine kinase
inhibitors have received special attention based on recent
clinical investigation of the two agents gefitnib and erlotnib.1
The cell cycle inhibitor pemetrexed and the proteosome
inhibitor bortezomib are both approved for use in other
cancers and have some promise in the treatment of lung
cancer.2,3 Clinical trials investigating several other molecular
agents that inhibit one or more pathways important for tumor
growth and development are underway. Other synthetic
agents, such as COX-2 inhibitors, thalidomide, and thalido-
mide analogs (CC-5013 and CC-4047), have well-character-
ized immune-modulating effects and may be useful additions
to the repertoire of immunotherapeutic strategies.4,5
Gene Therapy
Gene therapy is more of a drug delivery system than an
actual therapy in itself. The ability of gene transfer vectors to
deliver a therapeutic gene to an organ, region, or cell type
(e.g., malignant tumor) can be applied to many different
scenarios and targeted therapeutic approaches. Focal expres-
sion of a gene product achieves high concentrations of a
therapeutic protein intracellularly or secreted within the local
milieu and thereby spares non-targeted tissues from the ef-
fects of the expressed protein. Because the designation of
gene therapy as a therapy can be misleading, an appropriate
distinction should be made between gene transfer vectors and
gene-based therapeutic proteins. Oncogenic viruses are a
notable exception because the innate cytolytic properties of
these viruses are being used therapeutically.
Immunotherapy
Immunotherapy is an old concept based on the knowl-
edge that the immune system can discriminate cancer cells
from normal cells. Immunotherapy can be categorized as
either passive or active. Passive immunotherapy includes any
immunologically active agent that is made outside the body
and does not rely on host machinery to function. By contrast,
active immunotherapy uses the host’s immune cells and
requires an intact immune system to function. Anti-suppres-
sive therapy is a subcategory of active immunotherapy used
to reverse host and tumor factors that confer a survival
advantage to lung cancer.
Therapeutic antibodies are the prime example of pas-
sive immunotherapy. Monoclonal antibodies are being inves-
tigated for their ability to disrupt tumorigenic cascades by
blocking the binding of hormones or growth factors to their
receptors. Monoclonal antibodies currently under investiga-
tion in lung cancer include cetuximab and trastuzumab,
which target epidermal growth factor receptors HER-1 and
HER-2, respectively, and bevacizumab, which interferes with
tumor angiogenesis by binding to vascular endothelial growth
factor.6,7 Other examples of passive immunotherapy include
ex vivo amplification and infusion of autologous tumor infil-
trating T-cells (TIL therapy) or lymphokine activated killer
cells (LAK therapy).8,9 Before further discussion of active
immunotherapy, a brief review of immune recognition, tol-
erance, and lung tumor antigens is warranted.
Lung Cancer Immunobiology
Immune Recognition and Tolerance
Antigen-specific immune responses are dependent on
antigen presentation in the patient’s lymphoid tissues. When
antigen is contacted, antigen-presenting cells (APCs) digest
whole proteins into smaller peptides that are then presented
on HLA class I or class II molecules on the APC surface.
Depending on the type or source of antigen and the existing
cytokine milieu, class II peptides may stimulate IL2 and
IFN- release by antigen-specific CD4 T cells (T-helper 1
cells; Th1). Antigen-specific CD8 cytotoxic T lymphocytes
(CTLs) are generated when CD8 T cells bound to class I
antigens on APCs are stimulated by Th1 cytokines. Alterna-
tively, class II antigen binding may induce a different T cell
phenotype (T helper 2 cells; Th2) that releases IL4 and IL10 and
interacts with B cells to promote antigen-specific antibody pro-
duction. Whereas Th1 and Th2 are not necessarily mutually
exclusive in the immune response, Th2-related cytokines tend to
suppress Th1-mediated responses. Notably, activated Th1 cells
have longevity compared with other activated immune cells
(APCs and CTL) and are conventionally viewed as being re-
sponsible for “immune memory,” capable of “revitalizing” the
immune response if a specific antigen is reencountered.
Identification of tumor-associated antibodies and anti-
gen-specific CTL among patients with lung cancer indicates
that the immune system can distinguish lung cancer cells
from normal cells.10,11 The immune system, however, gener-
ally lacks the power to eradicate established disease.12,13
Physiological immune regulation is a major contributing
factor.12–14 Immune regulation prevents uncontrolled host
responses that can cause disease, as is the case with autoim-
mune phenomena.14,15 This autoregulation is the basis of
tumor tolerance, which is essentially the inability to mount an
appropriate anti-tumor immune response.12–15 Th2 cytokines,
APC senescence, and regulatory T cells all favor tumor
growth by ultimately dampening CTL responses to cancer
cells.12–14 Most established tumors also have mechanisms of
immune evasion.12,13,15 The production and induction of im-
munosuppressive cytokines has been well characterized.
Some tumor cells also avoid immune destruction by down-
regulating HLA class I molecules on which antigens are
presented for recognition or overexpressing B7-H1, a ligand
for the T cell receptor PD-1, which is known to negatively
regulate T-cell activation. CTL resistance and counter-de-
fense mechanisms, including tumor expression of the apop-
tosis-inducing molecule FAS ligand and down-regulation of
surface FAS receptors, have also been described.15 Immune
regulation, tolerance, and immune evasion are important
challenges to successful development of immunotherapy. The
goals of active immunotherapy thus include enhancing anti-
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gen recognition, augmenting effector mechanisms, and mod-
ulating regulatory or suppressive elements.
Lung Tumor Antigens
Ideal antigen targets for immunotherapy are those that
are highly aberrant or expressed in exceedingly high amounts
compared with normal tissues. Additionally, an ideal antigen
for immunotherapy should be uniformly expressed by all lung
cancers; however, phenotypic heterogeneity characteristic of
NSCLC and SCLC dictates high variability of antigen ex-
pression. There are four main categories of lung tumor
antigens. (1) Differentiation antigens are expressed in tumor
and normal tissues of the same lineage. Gangliosides are the
FIGURE 1. Immune induction. Immune recognition and
response is divided into a priming phase in which antigen is
processed, information is exchanged, and responses are or-
chestrated and an effector phase in which cytotoxic T cells
(CTL), natural killer cells (NK), and antibodies attack the im-
mune target. (1) Tumor antigens are shed by tumor into the
local milieu and ultimately end up in lymphatic circulation as
free antigen, antigen-antibody complexes, or antigens cap-
tured and processed by antigen-presenting cells/dendritic
cells (APC/DC). (2) Antigens travel, along with DCs and na-
ive lymphocytes, to the lymph node, the principal site of
cellular interaction. (3) In the lymph node, DCs orchestrate
the immune response. DCs process antigen and interact
with lymphocytes through cytokine production and expres-
sion of cell surface molecules. DCs are capable of directing a
versatile response. Naive T cells binding DCs via antigen-
specific T cell receptors differentiate into CD4 T-helper 1
or T-helper 2 cells (Th-1 or Th-2). These cells are responsible
for immune memory and driving cytotoxic or antibody re-
sponses, respectively. Antigen-specific CTLs are activated by
cytokines produced by Th-1 cells and DCs (IL12, IL2, IFN-).
NKs, which are antigen-independent, are also activated by
Th-1 cytokines. B cells interact with Th-2 cells and produce
antigen-specific antibodies. CD4CD25 T regulatory cells
(T-regs) are likely generated in parallel with the CTL re-
sponse. (4) CTL, NK, T-regs, and antibodies are released into
the bloodstream. (5) Cells are attracted to the site of tumor
by chemokines released by inflammatory cells and other
chemoattractants in the local milieu. An integrated immune
response is formed at the tumor site. Antibodies (plus com-
plement) have little cytotoxic effect on established tumors.
CTLs kill tumors that express specific antigen by perforin-
mediated cytotoxicity. NKs bind cells that do not express
MHC molecules and kill also by perforin-mediated cytotoxic-
ity. Cytotoxic anti-tumor effects can be dampened by the
action of T-regs that inhibit CD8CTL through direct cell-to-
cell contact in addition to the production of suppressive cy-
tokine production.
FIGURE 2. Antitumor immune induction, competing path-
ways, and avenues for immune regulation and suppression.
Tumor antigens stimulate both antibody responses and cyto-
toxic T-cell (CTL) responses via two independent and essen-
tially mutually excusive pathways. CTLs are the dominant
antitumor effectors, whereas antibodies are largely ineffec-
tive against established tumors. This schematic depicts
stages of immune activation toward antitumor CTL. The red
lines indicate inhibitory signals that attenuate these re-
sponses. In sequence, antigen is captured and processed by
immature dendritic cells (DCs) at the site of tumor, in circu-
lation, or in the regional lymph nodes. Antigen capture ini-
tiates T-cell binding, and cognate interaction induces both
DC maturation and T-cell activation. Cytokines and cellular
interaction drive DCs to mature toward a DC1 or DC2 phe-
notype that stimulate T helper 1 and 2 cells, respectively
(Th1/Th2). Th1 cells induce the desired anti-tumor CD8
CTL responses. Th2 cells interact with B cells to induce anti-
body production. Importantly, cytokines produced by Th2
cells, specifically IL-10 and IL-4, inhibit Th1 pathways. Tumor
cells can also produce or induce cytokines that have similar
inhibitory effects on DCs and Th1 activity, including IL10,
PGE-2 and TGF-. CTL responses can be further attenuated
through inhibitory effects of T-regulatory cells on CTL or be
rebuffed by a variety of tumor resistance mechanisms, in-
cluding down-regulation of HLA class I, down-regulation of
surface FAS receptors, over-expression of B7-H1, and over-
expression of FAS ligand.
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main example of differentiation antigens found in lung can-
cer.16 These surface antigens are found in growing and
developing tissues, especially of neuro-ectodermal origin,
and identified as aberrantly expressed in a number of malig-
nancies, including most SCLC. The family of gangliosides
includes GM2, GD2, GD3, 9-O-acetyl GD3, and fucosyl-
GM1 (Fuc-GM1).17 (2) Cancer testis antigens (CTA) are
shared among tumor types but are not expressed in normal
cells except in the immune privileged areas of the testis and
placenta. CTA include MAGE, GAGE, BAGE, and NY-
ESO-1.18 (3) Mutated antigens result from unique mutation of
normal genes, and because mutations are not similarly found
in normal tissues, these are, conceptually, ideal targets for
immunotherapy. Several lung tumor antigens are mutated at
predictable locations and in high enough frequency to serve
as reliable targets for antigen-specific vaccine immunother-
apy, including p53, k-ras, -actin, and EGFRvIII.19–21 Spo-
radic mutations that are unique to an individual tumor may be
important targets for autologous tumor vaccines that do not
require antigens to be specifically identified. (4) Overex-
pressed antigens are expressed by normal cells but are found
in considerably higher levels in cancer cells. Antigens found
in lung cancer include Her2/neu, survivin, MUC1, and car-
cinoembryonic antigen (CEA) and WT-1; each of these
antigens is also found in other solid tumors.22–27 CEA has
been investigated in numerous vaccine trials largely because
of its uniform expression in colon cancer.
Active Immunotherapy for Lung Cancer
Tumor antigen recognition is central to the therapeutic
effects of active immunotherapy. Approaches that directly
incorporate tumor antigen are conventionally referred to as
vaccines. Other approaches nonspecifically stimulate immune
cell reactivity or attenuate suppressive elements. Although
anti-suppressive therapies are not a new concept, the recent
characterization of CD4CD25 T-regulatory cells has gen-
erated great interest in this strategy, and further understand-
ing of immune regulation and tumor evasion is likely to yield
multiple additional avenues for therapeutic intervention.14,28
The ultimate goal of almost all active cancer immunotherapy,
regardless of the mechanism, is to expand CTLs capable of
recognizing tumor antigens presented by HLA class I mole-
cules on cancer cells. Additional objectives include priming
CD4 helper T cells that play a key role in immune mem-
ory.12,13,29,30 Vaccine-induced antibody responses are widely
viewed as having limited therapeutic efficacy in cancer,
although development of vaccines that induce host antibody
production to growth factors or growth factor receptors may
change this perception.13 One epidermal growth factor (EGF)
vaccine induces antibodies that bind circulating EGF to
deprive the tumor of this important growth factor.31 Another
B-cell peptide vaccine in clinical development (MVF-HER-
2628-647) induces antibodies that bind the same area of the
HER-2 extracellular domain as trastuzumab.32
Immune Active Agents and Adjuvants
For purposes of discussion, the tools used for active
immunotherapy will be divided into the following categories:
(1) pharmacological agents; (2) biological and chemical ad-
juvants; (3) recombinant cytokines and chemokines; (4) gene
transfer vectors, and (5) autologous DCs. Several approaches
have overlapping immunological mechanisms.
Pharmacological Agents
Most pharmacological agents used as immunotherapy
can be described as biological response modifiers that skew
the immune system toward more favorable production of
cytotoxic T cells. COX-2 inhibitors are a prime example. In
addition to a number of purported direct effects on tumor
growth and differentiation, COX-2 inhibitors have been
shown experimentally to enhance the induction and/or function
of CTL by inhibiting the enzyme responsible for the production
of immunosuppressive prostaglandin E2 and its downstream
effects.4 Clinical experience in lung cancer is preliminary.4
Other selective immune-modulating drugs that work through a
variety of mechanisms are under development.5,33
Biological and Chemical Adjuvants
Adjuvants have been used for decades as a key com-
ponent in antigen-specific immunotherapy to induce inflam-
mation, either at the site of tumor or used in conjunction with
exogenously supplied antigen. Biological adjuvants take ad-
vantage of the fact that they are immunogenic compounds,
naturally recognized as foreign and known to induce migra-
tion of APCs to the site of delivery. APCs responding to the
adjuvant stimulation are thus able to coincidentally capture
and process tumor antigens present in the inflammatory
milieu. The most commonly used biological adjuvants in-
clude Bacillus Calmette-Guerin (BCG), diphtheria toxoid,
and tetanus toxoid.12,29 Chemical adjuvants function similarly
to biological adjuvants as irritants that induce an inflamma-
tory response at the site of delivery; some may also provide
a matrix that sequesters antigen at a specific location, allow-
ing a timed release of antigen to APCs. Examples include,
aluminum hydroxide, montanide ISA 51, AS02B, and incom-
plete Freund’s adjuvant.12,34
Recombinant Cytokines and Chemokines
Systemically administered cytokines have been ex-
plored for decades as stand-alone agents to nonspecifically
activate CTL (and/or natural killer cells), to skew the immune
response toward a CTL response through effects on Th1 and
APCs, to induce APC differentiation and function, or to
promote HLA class I molecule expression on tumor cells.
Cytokines have also been combined with vaccines, most
notably by using cytokine-gene transfer to generate high local
concentrations of stimulatory cytokines at the site of antigen
delivery.12,34,35 GM-CSF and IL2 are the two most widely
investigated cytokines in clinical trials. The list of cytokines
is far too extensive to detail in this article; see references 12
and 35 for further discussion of therapeutic cytokine uses in
cancer. Chemokines are humoral molecules that attract im-
mune cells to the site of inflammation, and they have been
recently explored as a method of attracting APCs to a tumor
antigen source. Similar to cytokines, chemokines may be
used at the site of tumor or combined with exogenous antigen
to attract APCs to a site of vaccination.
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Gene Transfer Vectors
Gene transfer vectors have a variety of potential applica-
tions in active immunotherapy. Numerous cancer gene therapy
strategies use gene transfer vectors to transduce tumor cells with
stimulatory cytokines or costimulatory molecules ex vivo or in
vivo to make the cells more immune- stimulatory.12 This ap-
proach avoids toxicities associated with systemic cytokine ad-
ministration. Other gene-based vaccine strategies modify normal
cells in vivo to express and present tumor antigens. This ap-
proach can also be combined with in vivo gene-based cytokine
or co-stimulatory molecule expression. A secondary advantage
of viral gene-transfer vectors used in vivo or ex vivo is an
adjuvant stimulation of the immune system responding to viral
proteins. This may be an important factor in experimental
success with gene-based antigen vaccines.12
Autologous Dendritic Cells
Dendritic cells are professional APCs that possess all
the necessary elements to initiate and potentate an antigen-
specific immune response. Numerous small clinical trials
evaluating ex vivo antigen-loaded DCs among patients with
variety of solid and liquid tumors have been reported in the
literature,36 although information is difficult to glean from
this diverse group of studies. Regardless, numerous trials
have shown biological activity. The literature also indicates
that a percentage of individuals may derive therapeutic ben-
efit, although, as expected from phase I and II trials, reports
of clinical efficacy are anecdotal. There is a paucity of
research on DC vaccines for lung cancer.
Antigen Source
All antigen-specific immunotherapy approaches are be-
lieved to ultimately depend on the presentation of tumor
antigens to T cells by APCs, which occurs in the patient’s
lymphoid tissues.12 The access of APCs to antigens is thus
paramount. Tumor antigens can be derived from autologous
or allogeneic sources.12 There are theoretical advantages to
each approach. Autologous approaches include the use of
tumor in situ or incorporation of autologous tumor (generally
surgically obtained) into vaccines (whole tumor cells, tumor
lysates, or tumor-derived RNA). Using an autologous tumor
as a source of antigen creates a patient-specific vaccine that
circumvents the need to know the antigens a cancer ex-
presses. A disadvantage for use of autologous tumor in
vaccines is that adequate tumor must be available for vaccine
production. As such, this approach is essentially restricted to
individuals with a surgically resectable tumor and requires
special handling and processing. Nonetheless, autologous
vaccines have been shown to have immunological activity in
a number of studies.12 Variable responses to these vaccines
does, however, raise the theoretical concern that patients may
be immunologically tolerant to their own tumor antigens and
may not mount an effective anti-tumor response regardless of
the adjuvant chosen. The results of vaccination with autolo-
gous tumor cells genetically modified to secrete various
cytokines, including granulocyte-macrophage colony-stimu-
lating factor (GMCSF), have been most encouraging in pre-
clinical studies. Clinical investigation of GMCSF-secreting
autologous tumor cell vaccines will be discussed below.
By contrast, the use of allogeneic antigen does not
require access to the patient’s tumor. Allogeneic tumor anti-
gens can be delivered as a single antigen (which may require
tumor characterization) or used in combination as a multiva-
lent approach. Sources of allogeneic antigens include alloge-
neic tumor cell lines, recombinant protein (including gene
therapy-derived), and synthetic peptide.12,13,30 Whole proteins
are processed and presented by APCs via class II and class I
pathways to CD4 and CD8 T cells, respectively, and have
the potential to generate a response that includes immune
effectors and immune memory. HLA class I and class II
restricted peptides used in immunotherapy are essentially
“pre-processed” antigens.12 The use of peptides is attractive
because they are small and easily synthesized, they are
uniform, and they provide the simplest and most reproducible
immunological measures of vaccine efficacy. A disadvantage
for peptide use is a peptide’s designated restriction to a
specific HLA type that requires patient selection based on
FIGURE 3. Dendritic cell (DC) vaccines. Mononuclear cells
are harvested from peripheral blood of a patient. Leuka-
pheresis is generally required to obtain adequate numbers of
DC precursors cells to produce a vaccine product. Peripheral
blood mononuclear cells are cultured in the cytokines
GMCSF and IL-4 to drive differentiation of CD14 DC pre-
cursors to immature myeloid DCs. The cultured DCs are
phagocytic and readily take up particulate antigen in cul-
ture. DCs process antigen into smaller peptides that are pre-
sented on the surface of the DC on MHC class I or class II
molecules. A complete complement of co-stimulatory mole-
cules and stimulatory cytokines are expressed when the cells
are fully matured, which happens when DCs are stimulated
by CD40 ligand expressed on activated T cells or culture
with a panel of inflammatory agents that stimulate the DC
toll-like receptors (TLR). DC vaccines can be delivered to the
patient as immature antigen-loaded DCs that are matured
on contact with T cells in vivo or DCs matured in culture
with CD40 ligand or a variety of other molecules such as
lipopolysaccharide (LPS). The DCs injected under the skin or
intravenously migrate to regional lymph nodes and interact
with tumor-specific T-cell precursors. CTLs are released into
the peripheral circulation, then migrate into tissues where
they encounter and destroy antigen-expressing cells (e.g.,
tumor).
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HLA tissue typing. A specific criticism of using only HLA
class I restricted peptides in vaccines is that class I peptides
stimulate predominantly CD8 CTL, not the CD4 T-helper
cells responsible for immune memory that result from class II
peptide stimulation.12
Xenogeneic anti-idiotype antibodies are somewhat
unique antigen-mimic preparations, generated as antibodies
to tumor antigen-binding sites on other antibodies (that generates
a template of the antigen). The foreign (xenogeneic) nature of
these preparations makes them inherently immunogenic, and the
similarity of the anti-idiotype antibody to the tumor antigen
allows cross-recognition of the parent/native protein.37
Immunological Monitoring
Immunological endpoints are critical for determining
the biological activity of vaccines in phase I and II studies. To
date, there is no standard assay or consensus on what consti-
tutes a positive immunological response.38 Considerations
when choosing assays for analysis include the information
desired (induction of antibody, T cell, or T-cell subsets), the
number of samples to be assayed, and the volume of sample
obtainable from each subject on serial blood draws. Serum
antibody measurement, used as an endpoint in some cancer
vaccine trials, is well established, standardized, simple, and
accurate. Discussion to follow will focus on measurement of
antigen specific T cells in samples from immunized patients.
See references 38 and 39 for a comprehensive discussion of
tools for immunological monitoring of the cancer vaccine
trial described below.
Functional assays include cytotoxicty, proliferation,
and cytokine production assays that all measure T-cell reac-
tivity on antigen stimulation. Each is used to demonstrate
higher frequency of antigen-specific T cell in circulating
peripheral blood mononuclear cells (PBMC) after vaccination
compared with baseline (before vaccine). Interpretation is
based on the notable assumption that the T cell responses of
PBMC reflect responses in draining nodes or the site of
tumor, and analysis may over- or under-represent compart-
mental activity. In vitro cytotoxicity assays measure the
ability of T cells in peripheral blood samples to lyse [Cr51]-
labeled antigen-expressing targets (autologous or HLA-
matched tumor cells). Serial dilution of effector cells to target
cells (E:T ratio) provides a comparative measure of the
response strength. This is a relatively insensitive assay and
generally requires previous expansion of effecter cells; thus,
readouts may not be a true reflection of the actual precursor
frequency. Proliferation assays measure the response of
PBMC to antigen challenges, usually by [3H]-thymidine
incorporation, and reflect the antigen-induced clonal expan-
sion of CD4 and CD8 T cells. This assay is easy to
perform but is highly variable, and results are not generally
quantitative. Antigen-specific cytokine production assays
have been developed as an alternative to the cytotoxicity
assay. These assays facilitate multiple-sample analysis, re-
quire minimal sample usage, and can be readily performed in
replicate to enhance reproducibility. The principle of the
enzyme-linked immunospot assay (ELISPOT) and the intra-
celluar cytokine assay is to measure T-cell production of
cytokine (usually IFN-) on antigen stimulation. ELISPOT
uses a 96-well microtiter plate coated with an antibody
(similar to conventional ELISA) that binds cytokine released
by antigen-specific T cells incubated with antigen. Using a
labeled cytokine-specific secondary antibody, a “spot” is
visualized where the cytokine producing cell has been. Re-
sults are conventionally reported as an absolute or relative
increase in the number of antigen-specific T cells (spots) in a
patient’s pre-vaccine PBMC sample compared with the post-
vaccine sample. Cellular cytokine production can alterna-
tively be measured by flow cytometry using an intracellular
cytokine assay. This method has a moderately higher limit of
detection than ELISPOT and facilitates the measure of reac-
tive T-cell subsets.
Delayed type hypersensitivity (DTH) to antigen chal-
lenge is a qualitative functional assay performed in vivo.
Similar to the mantoux skin test for tuberculosis, a mononu-
clear cell response is mounted at the site of antigen challenge
if the patient has preexisting T cell immunity. This is a widely
used assay that can be practically applied to most vaccine
approaches. Sensitivity maybe limited, and results in clinical
trials have been variable. Preexisting immunity that may be
induced by a patient’s own tumor and host factors such as
immnosuppression can cloud the readout.
Tetramer staining is a non-functional, quantitative mea-
sure of antigen-specific T cell frequency in peripheral blood.
Florescent-labeled tetramers are constructed to bind a unique
MHC/peptide-specific T cell receptor, and tetramer-tagged T
cells are quantified by flow cytometry. MHC class I-peptide
tetramers used to measure CTLs specific for select antigens
are the most commonly available, although some MHC class
II-peptide tetramers have also been developed for the assess-
ment of CD4 T cell responses. Because tetramers are
specific for a single specific HLA-matched epitope, this assay
is most practical for use with HLA-restricted peptide vac-
cines, although tetramers are not available for all antigens or
all HLA types.
Immunological assays are critical measures of vaccine
potency. With all studies using primary immunological end-
points, there is also an assumption that immunological re-
sponse correlates with clinical benefit. Importantly, some
clinical trials have shown correlation between immunological
response (measured by a variety of assays) and clinical
response criteria within the study population (survival, pro-
gression, recurrence, radiographic and serologic measures).
An interesting finding in some clinical trials is the lack of
immunological response in patients showing clear clinical
response. This suggests that available immunological assays
may underestimate the relative clinical benefit to the patient.
Continued correlation of immunological and clinical response
criteria will provide important validation of immunological
endpoints that will ultimately assist in the development of
immunotherapies.
Clinical Vaccine Trials
In this section, we detail the published literature. These
are divided into (1) antigen  chemical/biological adjuvant;
(2) antigen  cytokine; (3) anti-idiotype  biological adju-
vant; (4) gene therapy; and (5) antigen-loaded DCs (a study
using nonprofessional antigen presenting cells is also include
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in this section). Clinical trials and results are also highlighted
in Tables 1–3.
Antigen  Chemical/Biological Adjuvant
In seven phase I/II trials, a total of 84 patients with
NSCLC and 29 patients with SCLC were treated with five
different antigens and six different adjuvant vaccines.31,40–44
Immunological enhancement with adjuvant was shown in one
comparative trial of antigen with and without adjuvant. An
optimal immunological adjuvant has not yet been defined.
Endpoints and objectives among these studies were varied
and included both immunological and clinical outcomes.
Immunological endpoints were dependent on the type of
antigen used (protein versus peptide) and reflected a primary
interest in class I or class II immune induction. In a study
conducted by Atanackovic et al.,40 the objectives were to
determine the ability of whole MAGE-3 protein to induce an
integrated class I and class II response measured by anti-
MAGE-3 antibodies and CD4 and CD8 T cells. In con-
trast, a prototypical peptide vaccine study by Oka et al.41 used
an HLA-A*2402-restricted class I peptide for WT-1 and used
antigen-specific CTL activity as the major endpoint. Two
studies assessed immunization of patients with SCLC with
either bovine or synthetic fucosyl-GM1 protein plus an ad-
juvant, with the endpoint of inducing antigen specific anti-
bodies.42,43 The interest in antibody induction was based on
the observation that the presence of anti-GM2 antibodies is
associated with prolonged disease-free survival in melanoma
patients. This interest was furthered by results from a related
phase I study that showed that patients with SCLC who were
immunized with a GM3 anti-idiotypic vaccine (BEC2) had a
prolonged survival compared with historical controls. Toxic-
ity was limited in each of the above-referenced trials, al-
though an interesting side effect peculiar to the fucosyl-
GM1–based vaccine was mild sensory neuropathy in 3 of 16
subjects, presumably because of fucosyl-GM1 expression in
sensory neurons. All trials showed immunological efficacy,
although the clinical relevance remains unclear. Importantly,
Oka et al.41 also measured clinical response criteria after
WT-1 vaccine that included tumor marker levels (CEA SCC
or SLX), radiographic changes, and clinical stability. The
authors observed a significant correlation between immuno-
logical and clinical responses in all the patients examined
(patients with breast or lung cancer or leukemia). Interest-
ingly, although 8 of 11 patients with clinical responses had
immunological responses, three showed no immunological
response (including one of four patients with lung cancer with
clinically stable disease). Conversely, two of the eight pa-
tients with no clinical response had immunological responses.
Antigen  Cytokine
Only one study has evaluated the use of antigen plus
cytokine as an adjuvant in one stage III patient with NSCLC
and nine patients with breast cancer.45 The vaccine (delivered
TABLE 1. Clinical Vaccine Trials: Antigen  Adjuvant (Chemical/Biological/Cytokine)
Antigen (name) Vaccine description Tumor/Stage Phase trial
Patient N lung 
other
Immunological
assay (No.
responders/total)
Clinical response
criteria (immune
assay correlation) Reference
WT1 WT1 peptide 
montanide ISA 51
NSCLC IV I/II 10,  2 breast,
12 leukemia
Tetramers, IC
cytokine (13/23
evaluable)
Serologic
radiographic
survival (positive)a
41
MUC1(BLP25) MUC-1 peptide 
liposome
NSCLC IIIB/IV I 17 (12 completed) MUCI-Ab.
Cytotoxicity
proliferation (5/12)
Anecdotal (N/A) 44
Epidermal growth
factor
EGF/carrier protein
aluminum OH
or montanide ISA
51
NSCLC IIIB/IV I 40 (2 trials) Anti-EGF Ab (19/40) Progression/survival
(positive)
31
MAGE-3 MAGE protein /-
AS02B
NSCLC I/II I 17 IC cytokine,
tetramers
ELISPOT, MAGE-
Ab 3/9 no adjuvant
8/8 with adjuvant
None (N/A) 40
GM1 (bovine or
synthetic )
GM1 protein/KLH 
QS-21
Small cell I 29 (2 trials) GM1-Ab/Ab-
mediated lysis (18/
29-dose dept)
Anecdotal (N/A) 42, 43
Her 2 Her 2 class II multi-
peptide  GMSCF
NSCLC III I One  9 breast Proliferation/ Her2-
Ab (5/10 to Her
peptide; 0/10 to
native Her2)
None (N/A) 45
Anti-idiotype
GD3 (BEC2)
GD3 protein BCG Small cell
limited stage
III n  257/258
randomized
GD3-Ab Progression/survival
phase I (positive)
phase III (no
benefit)
17, 46
Ab, antibody; IC, intracellular; KLH, keyhole limpet hemocyanin.
a Of the 11 patients with partial or complete clinical response, 8 had immunological responses, but 3 showed no immunological response.
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intradermally) is composed of four class II restricted HER-
2/neu peptides plus 125 g GM-CSF. This study is unique in
its selective use of class II peptides intended to induce CD4
T helper cells as a way of ultimately generating an integrated
antigen-specific effector response and immune memory.
Roughly half the patients developed either T cell or antibody
response (or both) to the peptides used in the vaccine but,
interestingly, not to the native Her2/neu protein.
Anti-Idiotype  Biological Adjuvant
Only one anti-idiotypic vaccine has been evaluated in
lung cancer and is the only lung cancer vaccine to have been
used in phase III studies. In the initial phase I trial, patients
with limited-stage SCLC achieving a partial or complete
response from chemotherapy were vaccinated with an anti-
idiotype GD3 monoclonal antibody (BEC2) and BCG. Those
TABLE 2. Clinical Vaccine Trials: Gene Therapy
Antigen
(name) Vaccine description Tumor/stage Phase trial
Patient N
lung  other
Immunological
assay (No.
responders/total)
Clinical response
criteria (immune
assay correlation) Reference
MUC1
(TG4010)
vaccinia/MUC1/IL2 NSCLC IIB/IV
treatment naive
II 65, randomized
/- chemo Rx
Proliferation (5/13
reported)
Progression/survival
(not reported)
49, 50
CEA
(ALVAC)
canarypox/CEA/B7.1 NSCLC IV
CEA tumors
I/II 3 15 GI ELISPOT (4/18) Progression/survival
(positive)
51
Allo-tumor
(AD100)
Allo-tumor/B7.1/HLA
A1 or A2 cDNA
NSCLC IIIB/IV I/II 19 ELISPOT (18/19) Progression/survival
(6/19 with PR or
SD)
47
Autologous
tumor
(GVAX)
Autologous tumor/
adenovirus/GMCSF
NSCLC I-IV II 43a (10 early
stage 33
advanced stage)
DTH (10/43) Progression/survival
(negative)b
48
Allo, allogeneic; Auto, autologous; PR, partial response; SD, stable disease; NSCLC, non–small-cell lung cancer; DTH, delayed type hypersensitivity.
a There were 83 tumors harvested, 67 vaccines produced, 43 delivered.
b Three of three patients with complete clinical response and one of three with partial clinical response showed no immunological response.
TABLE 3. Clinical Vaccine Trials: Antigen Presenting Cells
Antigen
Vaccine
description Tumor/stage Phase trial
Patient N lung
 other
Immunological
assay (No.
responders/total)
Clinical response
criteria (immune
assay correlation) Reference
Antigen
Loaded
Dendritic
Cells
MUC1 or Auto-
tumor
MUC1 peptide (n
 8) MUC1neg
autologous tumor
lysate (n  6)
NSCLC IIIB/IV I/II 8,  6 breast
MUC1pos 9
MUC1neg 5
Cytotoxicity
(MUC1
pos
9/9)
(MUC1
neg
1/5)
Progression/survival
(positive -
correlated with
MUC1expression)
55
CEA HLA-A24 restricted
peptide
(CEA652)
a
NSCLC IV
CEA tumors
I/II 2,  8 GI DTH (2/10) Anecdotal (N/A) 54
CEA HLA-A0201
peptide (CEA605–
613)/KLH
NSCLC IV
CEA tumors
I/II 2,  10 GI Tetramer/
proliferation (7/
12)
Progression/survival
(positive)
53
CEA RNA/
Auto-RNA†
CEA mRNA and
Auto-tumor RNA
NSCLC IV
CEA tumors
I 1b,  1 colon,
1 melanoma
Cytotoxicity (1/1) None 56,57
Allo-tumor Allo-tumor NSCLC I-IIIB I/II 16 ELISPOT (11/16) Anecdotal (N/A) 52
Antigen 
non-
professional
APC
p53 k-ras Mutant peptide 
PBMC
NSCLC IV
(n9) II
(n1)
I/II 10,  1
ovarian, 23
GI, 3 breast,
1 head &
neck
Cytotoxicity,
cytokine release
(IFN gamma)
(17/38)
Progression/survival
(positive)
21
Allo, allogeneic; Auto, autologous; NSCLC, non–small-cell lung cancer; DTH, delayed type hypersensitivity.
a Seven subjects also systemically received recombinant IFN- and TNF- as immune adjuvants.
b The same patient with NSCLC received both DC/CEAmRNA then DC/autologous tumor mRNA vaccines upon disease progression (two trials).
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who developed anti-GD3 antibodies had prolonged survival
compared with historical controls. These encouraging results
led to the phase III trial that disappointingly did not show a
similar clinical benefit. The results of this trial were reported
at the American Society for Clinical Oncology meeting in
2004.17,46
Gene Therapy
A total of 130 patients with NSCLC have been treated
in four phase I/II studies. Each study has unique aspects that
provide proof of principle for selected gene therapy strate-
gies. Each used a different vector for gene transduction. Two
used in vivo strategies and two used ex vivo strategies. One
study evaluated a vaccine composed of the allogeneic ade-
nocarcinoma cell line (AD100) transfected with B7.1
(CD80), a co-stimulatory molecule expressed by antigen-
presenting cells intended to turn the tumor cell into a non-
professional antigen-presenting cell.47 The cell line was also
transduced with HLA A1 or A2 and used in patients with
corresponding HLA type, which would then allow direct
antigen presentation by vaccine cells to T cells. Six patients
that were non HLA A1 or A2 were also immunized, with the
reasoning that AD100 lysis or death would release tumor
antigens that could be secondarily processed by the host’s
professional antigen-presenting cells and presented to T cells.
All but one patient showed measurable CD8 immunological
response despite the fact that the antigen was not appropri-
ately HLA matched for 6 of the 19 subjects. Minimal toxicity
and good survival in this small population suggest clinical
benefit from vaccination. A second study evaluated an autol-
ogous tumor cell vaccine (GVAX) in 33 patients with ad-
vanced and 10 with early-stage NSCLC. Autologous tumor
obtained from surgery was transduced ex vivo with an ad-
enoviral vector delivering GMCSF cDNA to processed tumor
cells. Of the 33 patients with advanced NSCLC, 3 achieved
complete response and prolonged remission; 2 of these pa-
tients had bronchoalveolar cell carcinoma. Of the 10 patients
with early-stage lung cancer, 8 remained free of disease with
a median follow-up time of 12 months. Roughly half showed
immunological response measured by DTH to irradiated
autologous tumor cells. Interestingly, none of the three pa-
tients with advanced stage disease and complete clinical
response had a measurable immune response by DTH, and
only one of the three patients with minor clinical responses
showed positive DTH. Another important aspect of this study
was that, of 83 tumors harvested, 16 vaccines could not be
successfully generated, and 11 other patients died before the
vaccine could be delivered. The median production time was
31 days, and median time from tumor harvest to immuniza-
tion was 49 days. Forty-three patients were immunized.48
Two studies evaluated in vivo gene therapy approaches.
Viral vectors carrying cDNA for MUC1 or CEA were in-
jected intramuscularly to achieve antigenic protein expression
within the patient’s normal cells. Both vaccines also included
genes for immune stimulatory adjuvants to enhance antigen
recognition. MVA-MUC1-IL2 (TG4010)49,50 vaccine carries
cDNA for IL2 to induce T-cell activation. CEA/B7.1 canary-
poxvirus vaccine (ALVAC)51 delivers the T cell co-stimula-
tory molecule B7.1, again to induce T-cell activation. Both
studies showed antigen-specific immune responses and anec-
dotal clinical benefit.
Antigen-Loaded Dendritic Cells
Thirty-four patients with NSCLC received vaccines in
five studies using autologous DCs to present a variety of
antigens. All DC vaccine studies used a similar approach of
autologous DC precursor harvest by leukapheresis and cul-
ture in GMCSF and IL4 to induce DC differentiation.52–57
Antigens are readily taken up by cultured autologous DCs,
which then process and present antigens in vivo to CD8
CTL (via HLA class I) and CD4 T helper cells (via HLA
class II) using a full complement of co-stimulatory molecules
and cytokines. The maturation state of DCs used in vaccines
is not standardized, although the prevailing bias is that anti-
gen-loaded DCs, activated ex vivo, express higher levels of
co-stimulatory molecules and cytokines and are thus most
appropriate for vaccine use. Both immature and matured DC
vaccines have been shown to induce antigen-specific immu-
nity, although comparative studies have not been per-
formed.36
In a prototypical DC approach, Hirschowitz et al.52
intradermally immunized 16 subjects with stage I-IIIB
NSCLC with a partially matured autologous DC vaccine
pulsed with an allogeneic tumor cell line that expressed a
complement of five known NSCLC antigens (MAGE, WT1,
survivin, CEA, Her2/neu). Objectives were to define whether
stage or previous therapy was a limitation to the successful
induction of immunological response in NSCLC. Individuals
of various stages were enrolled after completion of definitive
surgery, chemotherapy/radiation, or multimodality therapy.
Data showed that 11 of 16 patients had immunological
response, 6 of 16 of which were specific for the known
antigens delivered. Neither stage nor previous therapy
seemed to be a limitation to achieving immunological re-
sponse. Clinical benefit could not be confirmed, although
based on stage, some individuals with stage III NSCLC did
clinically better than expected.
Two studies evaluated DC vaccines incorporating
HLA-restricted class I CEA peptides in patients with corre-
sponding HLA type (HLA-A0201 and HLA-A24 respec-
tively). Fong et al.53 used a CEA peptide modified by single
amino acid substitution (CEA 610D) and showed that this
vaccine induced CTL activity specific for both the CEA 610D
peptide and the native CEA peptide in 7 of 12 patients.
Tetramer analysis revealed that more than 1% of peripheral
CD8 T cells were specific for 610D in 5 of 12 patients.
Clinically, 2 of 12 patients had complete clinical responses,
and 3 others had measurable disease stability, although all
ultimately progressed. There was a statistically significant
correlation between clinical response and both the percentage
of specific CD8 cells on tetramer assay and antigen-specific
proliferation of CD8 over baseline. This immunological
and clinical correlation is the most significant aspect of this
study. In contrast to these results, Itoh et al. 54 found limited
immunological responses to HLA-A24 CEA652-pulsed DC
vaccine. The minor immunological responses seen in this trial
may have resulted from the use of robust, but not particularly
sensitive, immunological measures (DTH and antigen-spe-
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cific CTL) or from the fact that the CEA652 peptide itself has
limited antigenicity. Minor clinical responses were noted, but
it is unclear whether clinical responses were the result of
adjuvant IFN- and TNF- systemically administered to 7 of
10 patients at the time of immunization to enhance immune
induction.
Kontani et al.55 evaluated autologous DC vaccines
loaded with either MUC-1 peptides in patients with MUC1-
positive tumors (n  8) or autologous tumor lysates in
patients with MUC1-negative tumors (n 5; one patient with
MUC1-positive tumor also received autologous tumor lysate
vaccine). These investigators then compared the immunolog-
ical and clinical effects of the two preparations. After vacci-
nation, all the patients with MUC1-positive tumors acquired
MUC-1 antigen-specific immunity, whereas only one of five
individuals with MUC1-negative cancer showed immunolog-
ical response to antigens expressed by their own tumor.
Clinically, marked effects such as reduction in tumor sizes or
tumor marker levels or disappearance of malignant pleural
effusion were observed in seven of the nine MUC1-positive
cases. Survival of patients with MUC1-positive tumors re-
ceiving peptide-pulsed DCs was significantly better than
patients with MUC1-negative tumors receiving autologous
tumor-based vaccines (mean survival 16.75 versus 3.80
months, p  0.0101). The authors showed that MUC1 is
immunogenic and that vaccine-induced immune responses
may correlate with clinical benefit. Data may also suggest
that targeting dominant antigens with peptide-pulsed DCs
may afford better therapeutic efficacy than allogeneic tumor-
pulsed DCs, although no definitive conclusions can be drawn
from this single small study.
Using a rather unique autologous tumor approach, Nair
et al.56 transfected DCs with autologous tumor RNA using
lipid transfection. This approach seemed to induce strong
CTL responses to antigen(s) expressed by the parent tumor.
The advantage of this approach is that only small amounts of
autologous tumor are required for vaccine production, as a
limited amount of RNA can be amplified using standard
polymerase chain reaction.57
Carbone et al.21 investigated a related, but somewhat
unique, approach to that described with DC vaccines. The
subject population was screened for mutations in p53 or
k-ras, and a peptide with the corresponding mutation was
custom-synthesized. The investigators used irradiated PBMC
as nonprofessional antigen-presenting cells that were mixed
with peptides and delivered intravenously every 2 months for
a total of four immunizations (assuming no tumor progres-
sion). Immunological responses were noted in 17 of 38
subjects using one of two assays. Prolonged survival in the
group with advanced malignancy was associated with immu-
nological response measured by either assay. Although the
study population was small and heterogeneous, the immuni-
zation of advanced stage cancers with extremely poor prog-
nosis affords a useful measure of clinical efficacy (survival)
that can be accurately correlated with immunological analy-
sis. This study is unique in its use of nonprofessional APCs to
enhance peptide antigen presentation and the use of mutated
antigens for immunization. Interestingly, only 39 of the 226
patients screened were eligible for study, predominantly be-
cause of lack of suitable mutation in either gene, which
highlights the difficulty of targeting mutated antigens in lung
cancer and other malignancies. Nonetheless, this seems to be
an effective strategy for inducing antigen-specific T cells.
Future of Immunotherapy in Lung Cancer
Investigating immunotherapy for lung cancer is feasible
and rational. To date, no single therapeutic approach has risen
above another as the best. Data have shown that vaccines can
be safe, but definitive clinical benefit has not yet been
established. Clinical trials continue to explore numerous
promising approaches and permutations of lung cancer vac-
cines. Clinical development has, however, been hampered by
the fact that the production of most lung cancer vaccines is
labor-intensive and costly. Because large numbers of subjects
are required to statistically measure clinical efficacy, many
trials have stalled at phase I/II. The fact that the biological
assays used for monitoring of immunological endpoints are
far from standardized has further contributed to slow
progress. Appropriate criticism has been leveled at the equiv-
ocal relevance of various immunological assays and the fact
that comparative information is difficult to glean from the
published literature.36,38 Importantly, several studies have
shown some correlation between immunological response
and clinical response criteria within the study population,
although no study has definitively shown that immunological
response to vaccines translates into clinical benefit. This lack
of evidence does not, however, disprove the assumption, but
rather reflects the study objectives, trial size, and subject
heterogeneity. Further, the fact that most trials have targeted
advanced-stage lung cancers (and other metastatic malignan-
cies) that carry terminal prognoses and are notoriously resis-
tant to multiple therapies makes the information even more
difficult to interpret. Immunological endpoints will nonethe-
less continue to be important measures of vaccine potency,
especially during vaccine development stages. Correlation of
clinical response criteria and immunological responses will
ultimately be required to validate the clinical relevance of all
immunological endpoints in vaccine trials.Figure 1, Figure 2,
Figure 3.
A logical interim step in the transition from feasibility
to proof of clinical efficacy would be clinical trial designs that
incorporate appropriate clinical response criteria and well-
standardized immunological endpoints designated by consen-
sus among investigators in the field. We may then be able to
determine the dominance of certain approaches compared
with others. The next critical step in the transition requires
that therapies be optimized, refined, and simplified. In this
transition, we may see greater emphasis on allogeneic, rather
than autologous, vaccine approaches and the development of
more universal, multivalent, and off-the-shelf therapies.
Notably, facilitated methodology for characterizing antigen
profiles may lead to customized vaccines that could be
produced in a high volume. Additionally, once molecular
analysis is able to more accurately determine which individ-
uals are most likely to recur after surgical resection of
NSCLC, immunotherapy studies may be more rational and
efficiently conducted in a refined population with minimal
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residual disease in which immunotherapy is most likely to
provide therapeutic benefit. Ultimately, multiple immunolog-
ical approaches may be used in concert and potentially afford
better response than single-target approaches alone. Novel
pharmacological immune modulators, used alone or in com-
bination with vaccines, may contribute to significant thera-
peutic advances.
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